Back to Careers
Juvena Therapeutics Awarded Highly Competitive 3.9M CIRM TRAN1 Grant to Advance Lead Program, JUV-161, to Treat Myotonic Dystrophy Type 1
Back to Careers
Hanadie served on a CEO panel with a group of portfolio companies for Bascom Ventures (part of Alumni Ventures)
Back to Careers
CIRM Awards Juvena a $3.9M TRAN1 Grant to Advance JUV-161 for Myotonic Dystrophy Type 1 (DM1)
Back to Careers
CEO Dr. Yousef Represents Juvena at Longevity Summit 2021
Back to Careers
CEO Dr. Yousef Represents Juvena at Metabesity 2021
Back to Careers
CEO Dr. Hanadie Yousef Interviewed for Translating Aging Podcast, “The Cures Within Us”
Back to Careers
Juvena Therapeutics Presents at the Muscular Dystrophy Association Insights in Research Investor Summit
Back to Careers
Juvena Therapeutics Interviewed by Fortune Jan. 2021
Back to Careers
Juvena Therapeutics Presents at the International Longevity Alliance Conference Workshop Feb 2021
Back to Careers
Juvena Therapeutics at Metabesity Oct 2020 Conference
